Form 4: Krystal Biotech CEO Sells Shares
Insider Transaction (Form 4)
Krish S Krishnan, President and CEO, a Director and 10% owner of Krystal Biotech, Inc., sold 25,000 shares of common stock on September 4, 2026.
Summary
- Open-market sale: disposed of 520 Common Stock at $354.54 ($184,361) on September 4, 2026; holds 1,372,023 after (Direct).
- Open-market sale: disposed of 2,029 Common Stock at $355.57 ($721,455) on September 4, 2026; holds 1,369,994 after (Direct).
- Open-market sale: disposed of 3,297 Common Stock at $356.37 ($1,174,948) on September 4, 2026; holds 1,366,697 after (Direct).
- Open-market sale: disposed of 3,981 Common Stock at $357.57 ($1,423,501) on September 4, 2026; holds 1,362,716 after (Direct).
- Open-market sale: disposed of 3,143 Common Stock at $358.42 ($1,126,508) on September 4, 2026; holds 1,359,573 after (Direct).
- Open-market sale: disposed of 3,357 Common Stock at $359.39 ($1,206,459) on September 4, 2026; holds 1,356,216 after (Direct).
- Open-market sale: disposed of 2,266 Common Stock at $360.46 ($816,809) on September 4, 2026; holds 1,353,950 after (Direct).
- Open-market sale: disposed of 1,214 Common Stock at $361.61 ($438,993) on September 4, 2026; holds 1,352,736 after (Direct).
- Open-market sale: disposed of 2,010 Common Stock at $362.65 ($728,927) on September 4, 2026; holds 1,350,726 after (Direct).
- Open-market sale: disposed of 573 Common Stock at $363.34 ($208,195) on September 4, 2026; holds 1,350,153 after (Direct).
- Open-market sale: disposed of 1,358 Common Stock at $364.48 ($494,963) on September 4, 2026; holds 1,348,795 after (Direct).
- Open-market sale: disposed of 847 Common Stock at $365.42 ($309,508) on September 4, 2026; holds 1,347,948 after (Direct).
- Open-market sale: disposed of 405 Common Stock at $366.56 ($148,455) on September 4, 2026; holds 1,347,543 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $8,983,084 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Krish S Krishnan — Director, Officer (President and CEO), 10% owner
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-04 | Open-market sale | Common Stock | 520 | $355 | $184.4K | 1,372,023 |
| 2026-09-04 | Open-market sale | Common Stock | 2,029 | $356 | $721.5K | 1,369,994 |
| 2026-09-04 | Open-market sale | Common Stock | 3,297 | $356 | $1.2M | 1,366,697 |
| 2026-09-04 | Open-market sale | Common Stock | 3,981 | $358 | $1.4M | 1,362,716 |
| 2026-09-04 | Open-market sale | Common Stock | 3,143 | $358 | $1.1M | 1,359,573 |
| 2026-09-04 | Open-market sale | Common Stock | 3,357 | $359 | $1.2M | 1,356,216 |
| 2026-09-04 | Open-market sale | Common Stock | 2,266 | $360 | $816.8K | 1,353,950 |
| 2026-09-04 | Open-market sale | Common Stock | 1,214 | $362 | $439.0K | 1,352,736 |
| 2026-09-04 | Open-market sale | Common Stock | 2,010 | $363 | $728.9K | 1,350,726 |
| 2026-09-04 | Open-market sale | Common Stock | 573 | $363 | $208.2K | 1,350,153 |
| 2026-09-04 | Open-market sale | Common Stock | 1,358 | $364 | $495.0K | 1,348,795 |
| 2026-09-04 | Open-market sale | Common Stock | 847 | $365 | $309.5K | 1,347,948 |
| 2026-09-04 | Open-market sale | Common Stock | 405 | $367 | $148.5K | 1,347,543 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-04 | Open-market sale (520 shares) |
| 2026-09-04 | Open-market sale (2,029 shares) |
| 2026-09-04 | Open-market sale (3,297 shares) |
| 2026-09-04 | Open-market sale (3,981 shares) |
| 2026-09-04 | Open-market sale (3,143 shares) |
| 2026-09-04 | Open-market sale (3,357 shares) |
| 2026-09-04 | Open-market sale (2,266 shares) |
| 2026-09-04 | Open-market sale (1,214 shares) |
| 2026-09-04 | Open-market sale (2,010 shares) |
| 2026-09-04 | Open-market sale (573 shares) |
| 2026-09-04 | Open-market sale (1,358 shares) |
| 2026-09-04 | Open-market sale (847 shares) |
| 2026-09-04 | Open-market sale (405 shares) |
Keywords
insider transaction, Form 4, KRYS, Krystal Biotech, Inc., bearish, Krish S Krishnan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.